This email provides an up-to-date overview of the National Cancer Institute's Brain Cancer clinical trial portfolio in the ETCTN.

You will find information on:

- Active Brain Cancer trials & recent amendments
- Top accruing sites to Brain Cancer trials
- Brain Cancer protocols activating soon
- Brain Cancer protocols in development
- Notes/Updates from NCI CTEP

### Active Brain Cancer Trials & Recent Amendments

**Document Title:** (9952) Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC).

- **Accrual Goal:** 46
- **Planned Accrual Rate:** 6/mo
- **Current Accrual:** 5
- **Principal Investigator:** Mohindra, Pranshu
- **Principal Investigator Email:** pmohindra@som.umaryland.edu
- **Lead Organization Name:** Mayo Clinic Cancer Center LAO (LAO-MN026)

**Document Title:** (9979) Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-
Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

**Accrual Goal:** 47  
**Planned Accrual Rate:** 2/mo  
**Current Accrual:** 2  
**Principal Investigator:** Mohindra, Pranshu  
**Principal Investigator Email:** pmohindra@som.umaryland.edu  
**Lead Organization Name:** Mayo Clinic Cancer Center LAO  
(LAO-MN026)

---

**Document Title:** (10042) A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases

**Accrual Goal:** 98  
**Planned Accrual Rate:** 3/mo  
**Current Accrual:** 0  
**Principal Investigator:** Goldberg, Sarah B.  
**Principal Investigator Email:** sarah.goldberg@yale.edu  
**Lead Organization Name:** Yale University Cancer Center LAO  
(LAO-CT018)

Recent amendments & updates: Trial is once again open to accrual.

---

**Document Title:** (10067) A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

**Accrual Goal:** 70  
**Planned Accrual Rate:** 7/mo  
**Current Accrual:** 30  
**Principal Investigator:** Arrillaga-Romany, Isabel  
**Principal Investigator Email:** iarrillaga@mgh.harvard.edu  
**Lead Organization Name:** Dana-Farber - Harvard Cancer Center LAO  
(LAO-MA036)

---

**Top Accruing Sites to Brain Cancer Trials**

- Massachusetts General Hospital Cancer Center  
- UC San Diego Moores Cancer Center  
- Ohio State University Comprehensive Cancer Center

A big thank you to our top accruing sites across active
### Brain Cancer Protocols Activating Soon

**Document Title:** (10218) A Phase Ib Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

**Expected Activation Date:** 2/8/2019

**Principal Investigator:** Kizilbash, Sani Haider  
**Principal Investigator Email:** kizilbash.sani@mayo.edu  
**Lead Organization Name:** Mayo Clinic Cancer Center LAO (LAO-MN026)

### Brain Cancer Protocols in Development

**Document Title:** (10186) A Phase I/II Study Hypofractionated Radiation Therapy in Combination with Nivolumab and Ipilimumab for Recurrent High-Grade Radiation-Refractory Meningioma

**Expected Activation Date:** 9/7/2018

**Principal Investigator:** Huang, Jiayi  
**Principal Investigator Email:** jiayi.huang@wustl.edu  
**Lead Organization Name:** Duke University - Duke Cancer Institute LAO (LAO-NC010)

**Document Title:** (10220) Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1 and LKB1 Aberrant Tumors

**Expected Activation Date:** 2/8/2019

**Principal Investigator:** Subbiah, Vivek  
**Principal Investigator Email:** vsubbiah@mdanderson.org  
**Lead Organization Name:** University of Texas MD Anderson Cancer Center LAO (LAO-TX035)
Congratulations to Dr. Jeff Moscow on his appointment to Branch Chief of the Investigational Drug Branch (IDB) in NCI's Cancer Therapy Evaluation Program (CTEP) in the Division of Cancer Treatment and Diagnosis (DCTD).

The ETCTN competitive renewal grant was approved by NCI to go the Board of Scientific Advisors (BSA) for review at their upcoming meeting on June 26, 2018.

Check out NCI-CTEP's Twitter account! @NCICTEP_ClinRes

Interested in receiving newsletters for other types of cancer clinical trials? Click here.

Questions or feedback? Email us at ET-CTN@mail.nih.gov

This email was sent to masseth@mail.nih.gov